tradingkey.logo
tradingkey.logo
Search

Acurx Pharmaceuticals Inc

ACXP
Add to Watchlist
1.440USD
+0.020+1.41%
Close 07-31 16:00ETQuotes delayed by 15 min
4.88MMarket Cap
LossP/E TTM

ACXP Cash Flow Statement

You can access the annual and quarterly cash flow statements of Acurx Pharmaceuticals Inc to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
31.39%-1.41M
47.35%-1.18M
14.10%-1.88M
42.00%-1.67M
33.02%-2.05M
46.39%-2.25M
-4.60%-2.19M
-82.68%-2.88M
-58.46%-3.06M
-180.68%-4.20M
3.97%-2.09M
20.80%-1.58M
-3.03%-1.93M
0.31%-1.50M
17.31%-2.18M
-503.58%-1.99M
-242.88%-1.88M
-56.31%-1.50M
-247.48%-2.64M
55.05%-329.81K
39.16%-547.14K
---959.75K
---758.76K
---733.75K
---899.29K
Net income from continuing operations
21.79%-1.68M
43.26%-1.58M
29.37%-1.99M
45.50%-2.25M
50.91%-2.15M
45.61%-2.78M
9.42%-2.82M
-19.64%-4.12M
-50.81%-4.38M
-56.86%-5.11M
12.05%-3.11M
-31.47%-3.45M
-8.72%-2.90M
-24.11%-3.26M
23.71%-3.54M
34.55%-2.62M
-81.11%-2.67M
-140.35%-2.63M
-253.14%-4.64M
-338.39%-4.00M
-15.26%-1.47M
---1.09M
---1.31M
---913.36K
---1.28M
Other non-cash items
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
100.00%0.00
-100.00%0.00
--0.00
--0.00
---66.50K
17.28%916.76K
--0.00
--0.00
--0.00
--781.70K
Change in working capital
86.75%-45.84K
354.26%17.74K
-238.04%-228.03K
1396.14%165.31K
-401.30%-345.98K
97.75%-6.98K
-12.22%165.19K
-98.96%11.05K
62.53%114.83K
-132.56%-310.15K
-64.99%188.19K
1323.61%1.06M
145.57%70.65K
159.70%952.46K
138.61%537.50K
-105.85%-86.80K
51.05%-155.03K
340.50%366.75K
-658.81%-1.39M
1101.32%1.48M
57.75%-316.71K
---152.50K
--249.14K
---148.15K
---749.66K
-Change in receivables
-115.44%-7.90K
-117.75%-8.21K
100.00%0.00
21.36%-40.21K
-60.42%51.13K
135.81%46.25K
---46.25K
---51.13K
--129.16K
---129.16K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-Change in prepaid expenses
-134.02%-143.81K
222.41%73.18K
-329.63%-104.68K
454.08%108.05K
25.18%-61.45K
42135.19%22.70K
388.88%45.59K
-83.28%19.50K
-240.75%-82.13K
-100.07%-54.00
92.86%-15.78K
-4.84%116.66K
4.48%58.35K
-69.04%72.85K
-18.77%-220.95K
1259.48%122.60K
118.31%55.85K
680.69%235.28K
-3624.69%-186.03K
1583.22%9.02K
-962.90%-304.96K
---40.52K
--5.28K
---608.00
--35.34K
-Change in payables and accrued expense
131.54%105.87K
37.79%-47.23K
-174.38%-123.35K
128.39%97.47K
-595.04%-335.66K
58.04%-75.92K
-18.69%165.85K
-95.49%42.67K
451.39%67.80K
-120.57%-180.94K
-71.20%203.97K
694.05%945.43K
105.83%12.30K
569.04%879.61K
158.71%708.20K
-110.79%-159.15K
-1694.12%-210.88K
217.41%131.47K
-594.62%-1.21M
1099.33%1.47M
98.50%-11.75K
---111.98K
--243.87K
---147.54K
---785.00K
-Change in other current assets
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--50.25K
---50.25K
----
----
----
----
----
----
----
----
----
Cash from non-recurring investing activities
Cash from operating activities
31.39%-1.41M
47.35%-1.18M
14.10%-1.88M
42.00%-1.67M
33.02%-2.05M
46.39%-2.25M
-4.60%-2.19M
-82.68%-2.88M
-58.46%-3.06M
-180.68%-4.20M
3.97%-2.09M
20.80%-1.58M
-3.03%-1.93M
0.31%-1.50M
17.31%-2.18M
-503.58%-1.99M
-242.88%-1.88M
-56.31%-1.50M
-247.48%-2.64M
55.05%-329.81K
39.16%-547.14K
---959.75K
---758.76K
---733.75K
---899.29K
Investing cash flow
Cash from non-current investing activities
Financing cash flow
Cash flow from continuous financing activities
3.93%3.11M
1356.74%2.83M
8.30%1.72M
865.24%3.09M
-33.73%2.99M
-95.79%194.55K
--1.59M
-90.96%320.21K
--4.51M
461963800.00%4.62M
-100.00%0.00
--3.54M
----
---1.00
--3.70M
-100.00%0.00
----
-100.00%0.00
-100.00%0.00
1216.28%14.80M
--0.00
--728.54K
--2.19M
--1.12M
--0.00
Net cash flow from debt Issuance/repayment
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
-100.00%0.00
--0.00
--0.00
--0.00
--66.50K
--0.00
Net cash flow from common stock issuance/repurchase
3.93%3.11M
657.40%1.47M
8.37%1.72M
90.58%610.26K
-30.49%2.99M
-91.90%194.55K
--1.59M
-90.96%320.21K
--4.30M
--2.40M
-100.00%0.00
--3.54M
----
--0.00
--3.70M
-100.00%0.00
----
-100.00%0.00
-100.00%0.00
3152.26%14.80M
--0.00
--1.79M
--1.74M
--454.98K
--0.00
Proceeds from issuance of warrants
----
--1.36M
--0.00
--2.48M
----
-100.00%0.00
--0.00
-100.00%0.00
--210.20K
--2.22M
-100.00%0.00
--73.00
----
--0.00
--13.00
----
----
----
----
----
----
----
----
----
----
Net cash flow from other financing activities
--0.00
--0.00
---1.04K
----
----
----
----
----
----
----
----
----
----
---1.00
----
----
----
----
-100.00%0.00
-100.00%0.00
--0.00
---1.06M
--455.87K
--602.68K
--0.00
Net cash from non-recurrent financing activities
Net cash from financing activities
3.93%3.11M
1356.74%2.83M
8.30%1.72M
865.24%3.09M
-33.73%2.99M
-95.79%194.55K
--1.59M
-90.96%320.21K
--4.51M
461963800.00%4.62M
-100.00%0.00
--3.54M
----
---1.00
--3.70M
-100.00%0.00
----
-100.00%0.00
-100.00%0.00
1216.28%14.80M
--0.00
--728.54K
--2.19M
--1.12M
--0.00
Net cash flow
Beginning cash balance
103.85%7.56M
2.50%5.91M
-4.66%6.06M
-47.94%4.64M
-50.41%3.71M
-18.29%5.76M
-30.45%6.36M
24.27%8.92M
-17.97%7.47M
-33.51%7.05M
0.59%9.15M
-35.23%7.18M
-29.69%9.11M
-26.64%10.61M
-46.82%9.09M
321.68%11.08M
308.10%12.96M
324.44%14.46M
765.85%17.10M
65.92%2.63M
27.87%3.18M
--3.41M
--1.97M
--1.58M
--2.48M
Current period cash flow changes
81.26%1.70M
180.22%1.65M
73.70%-157.33K
155.48%1.42M
-35.22%937.17K
-587.33%-2.06M
71.42%-598.29K
-230.15%-2.56M
174.85%1.45M
128.21%421.86K
-238.17%-2.09M
198.81%1.97M
-3.03%-1.93M
0.31%-1.50M
157.47%1.52M
-113.76%-1.99M
-242.88%-1.88M
-548.83%-1.50M
-284.09%-2.64M
3605.66%14.47M
39.16%-547.14K
---231.22K
--1.43M
--390.41K
---899.29K
Ending cash balance
99.29%9.25M
103.85%7.56M
2.50%5.91M
-4.66%6.06M
-47.94%4.64M
-50.41%3.71M
-18.29%5.76M
-30.45%6.36M
24.27%8.92M
-17.97%7.47M
-33.51%7.05M
0.59%9.15M
-35.23%7.18M
-29.69%9.11M
-26.64%10.61M
-46.82%9.09M
321.68%11.08M
308.10%12.96M
324.44%14.46M
765.85%17.10M
65.92%2.63M
--3.18M
--3.41M
--1.97M
--1.58M
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

What is operating cash flow?

Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Acurx Pharmaceuticals Inc Generate?

Acurx Pharmaceuticals Inc generated -6.79M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Acurx Pharmaceuticals Inc's Operating Cash Flow Change Year Over Year?

Acurx Pharmaceuticals Inc's operating cash flow increased by 34.63% year over year.

What is investing cash flow?

Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

What is financing cash flow?

Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Acurx Pharmaceuticals Inc's Financing Cash Flow Changed?

Acurx Pharmaceuticals Inc used 10.64M in financing activities in the latest quarter.

What is free cash flow and why does it matter for ACXP?

Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.